Pancreatic Cancer Research

ResearcherYale Cancer CenterActive in the last 2 years

Michael Cecchini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3504-0128; OpenAlex author ID A5055159334. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 3 papers

Papers 7

  1. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial. Co-author DOI 10.1001/jamaoncol.2024.1575↗
  2. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae155↗
  3. Deep-Transfer-Learning-Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Ca… Co-author DOI 10.1200/cci.24.00021↗
  4. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved… Co-author DOI 10.1007/s00261-021-03284-5↗
  5. Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System. Co-author DOI 10.21037/jgo-21-202↗
  6. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Bor… Co-author DOI 10.1097/mpa.0000000000001592↗
  7. EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance. Co-author DOI 10.6004/jnccn.2017.0151↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jill Lacy · 5 shared papers, 2017–2024 · strength 0.65
  2. Stacey Stein · 3 shared papers, 2020–2024 · strength 0.39
  3. Kimberly L. Johung · 3 shared papers, 2020–2024 · strength 0.39
  4. Adham Adel Jurdi · 2 shared papers, 2024 · strength 0.29
  5. Jay K. Pahade · 2 shared papers, 2020–2021 · strength 0.27
  6. Ronald R. Salem · 2 shared papers, 2020–2024 · strength 0.25
  7. Choong‐kun Lee · 1 shared paper, 2024 · strength 0.20
  8. Mi‐Suk Park · 1 shared paper, 2024 · strength 0.20
  9. Hye Jin Choi · 1 shared paper, 2024 · strength 0.20
  10. Seung‐seob Kim · 1 shared paper, 2024 · strength 0.20
  11. Sung Hyun Kim · 1 shared paper, 2024 · strength 0.20
  12. Sunkyu Kim · 1 shared paper, 2024 · strength 0.20
  13. Ho Kyoung Hwang · 1 shared paper, 2024 · strength 0.20
  14. Yang Guo · 1 shared paper, 2021 · strength 0.16
  15. Sreenivasa Rao Chandana · 1 shared paper, 2024 · strength 0.15
  16. Naomi H. Fei · 1 shared paper, 2024 · strength 0.15
  17. Abdullah Esmail · 1 shared paper, 2024 · strength 0.15
  18. Farshid Dayyani · 1 shared paper, 2024 · strength 0.15
  19. Pashtoon Murtaza Kasi · 1 shared paper, 2024 · strength 0.15
  20. Maen Abdelrahim · 1 shared paper, 2024 · strength 0.15
  21. Midhun Malla · 1 shared paper, 2024 · strength 0.15
  22. Giby V. George · 1 shared paper, 2024 · strength 0.15
  23. Anup Kasi · 1 shared paper, 2024 · strength 0.15
  24. Gregory P. Botta · 1 shared paper, 2024 · strength 0.15
  25. Diana L. Hanna · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.